High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform.

Bruno, Peter M; Timms, Richard T; Abdelfattah, Nouran S; Leng, Yumei; Lelis, Felipe J N; Wesemann, Duane R; Yu, Xu G; Elledge, Stephen J · Nat Biotechnol · 2023

basic_science · Level V

Where this comes from

Abstract

Identification of CD8<sup>+</sup> T cell epitopes is critical for the development of immunotherapeutics. Existing methods for major histocompatibility complex class I (MHC class I) ligand discovery are time intensive, specialized and unable to interrogate specific proteins on a large scale. Here, we present EpiScan, which uses surface MHC class I levels as a readout for whether a genetically encoded peptide is an MHC class I ligand. Predetermined starting pools composed of >100,000 peptides can be designed using oligonucleotide synthesis, permitting large-scale MHC class I screening. We exploit this programmability of EpiScan to uncover an unappreciated role for cysteine that increases the number of predicted ligands by 9-21%, reveal affinity hierarchies by analysis of biased anchor peptide libraries and screen viral proteomes for MHC class I ligands. Using these data, we generate and iteratively refine peptide binding predictions to create EpiScan Predictor. EpiScan Predictor performs comparably to other state-of-the-art MHC class I peptide binding prediction algorithms without suffering from underrepresentation of cysteine-containing peptides. Thus, targeted immunopeptidomics using EpiScan will accelerate CD8<sup>+</sup> T cell epitope discovery toward the goal of individual-specific immunotherapeutics.

Medical subject headings